Header Logo

Connection

ANITA DESWAL to Male

Back to Details
This is a "connection" page, showing publications ANITA DESWAL has written about Male.
ANITA DESWAL
Connection Strength
0.623
Male
  1. Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines-Heart Failure Registry. J Am Heart Assoc. 2021 04 06; 10(7):e018696.
    View in: PubMed
    Score: 0.023
  2. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int J Obes (Lond). 2020 07; 44(7):1561-1567.
    View in: PubMed
    Score: 0.022
  3. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.017
  4. Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. JACC Heart Fail. 2017 01; 5(1):56-63.
    View in: PubMed
    Score: 0.017
  5. ACP Journal Club. Review: In HF with reduced EF, nurse-led titration of HF drugs reduces hospitalizations and mortality. Ann Intern Med. 2016 Apr 19; 164(8):JC41.
    View in: PubMed
    Score: 0.016
  6. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014 Dec 30; 64(25):2743-9.
    View in: PubMed
    Score: 0.015
  7. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. Am J Cardiol. 2014 Jun 01; 113(11):1834-8.
    View in: PubMed
    Score: 0.014
  8. Incident cancer in patients with heart failure: causation or mere association? J Am Coll Cardiol. 2013 Sep 03; 62(10):887-8.
    View in: PubMed
    Score: 0.013
  9. Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction. Evid Based Med. 2013 Dec; 18(6):226-7.
    View in: PubMed
    Score: 0.013
  10. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012 Mar 13; 59(11):998-1005.
    View in: PubMed
    Score: 0.012
  11. Obesity, leptin, and incident heart failure. J Am Coll Cardiol. 2011 Oct 25; 58(18):1878-80.
    View in: PubMed
    Score: 0.012
  12. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011 Aug; 17(8):634-42.
    View in: PubMed
    Score: 0.012
  13. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011 Jan; 4(1):53-8.
    View in: PubMed
    Score: 0.011
  14. Predicting quality of life in veterans with heart failure: the role of disease severity, depression, and comorbid anxiety. Behav Med. 2010 Apr-Jun; 36(2):70-6.
    View in: PubMed
    Score: 0.011
  15. Mortality after hospitalization for heart failure in blacks compared to whites. Am J Cardiol. 2010 Mar 01; 105(5):694-700.
    View in: PubMed
    Score: 0.011
  16. Depression and anxiety in ambulatory patients with heart failure. Psychosomatics. 2009 Nov-Dec; 50(6):592-8.
    View in: PubMed
    Score: 0.010
  17. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009 Jul 28; 54(5):422-8.
    View in: PubMed
    Score: 0.010
  18. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007 Jul 03; 50(1):32-6.
    View in: PubMed
    Score: 0.009
  19. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. 2007 Apr 15; 25(8):913-24.
    View in: PubMed
    Score: 0.009
  20. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J. 2007 Apr; 153(4):515-22.
    View in: PubMed
    Score: 0.009
  21. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J. 2006 Aug; 152(2):348-54.
    View in: PubMed
    Score: 0.008
  22. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. Am J Cardiol. 2006 Apr 15; 97(8):1228-31.
    View in: PubMed
    Score: 0.008
  23. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J. 2005 Dec; 150(6):1233-9.
    View in: PubMed
    Score: 0.008
  24. Long-term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: the impact of renal insufficiency and noncardiac vascular disease. J Card Fail. 2005 Apr; 11(3):206-12.
    View in: PubMed
    Score: 0.008
  25. Variation by race in factors contributing to heart failure hospitalizations. J Card Fail. 2005 Feb; 11(1):23-9.
    View in: PubMed
    Score: 0.007
  26. Role and optimal dosing of angiotensin-converting enzyme inhibitor therapy. Heart Fail Clin. 2005 Apr; 1(1):25-37.
    View in: PubMed
    Score: 0.007
  27. Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction. Am J Cardiol. 2004 Oct 15; 94(8):1003-7.
    View in: PubMed
    Score: 0.007
  28. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 Aug 01; 12(8):964-987.
    View in: PubMed
    Score: 0.007
  29. Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. J Nucl Cardiol. 2024 Sep; 39:101909.
    View in: PubMed
    Score: 0.007
  30. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. Eur Heart J Cardiovasc Imaging. 2024 05 31; 25(6):754-761.
    View in: PubMed
    Score: 0.007
  31. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol. 2004 Mar 03; 43(5):778-84.
    View in: PubMed
    Score: 0.007
  32. SGLT2 Inhibitor Use and Risk of Clinical?Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2024 01; 12(1):67-78.
    View in: PubMed
    Score: 0.007
  33. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis. 2022 May; 115(5):315-330.
    View in: PubMed
    Score: 0.006
  34. Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure. Heart Fail Monit. 2002; 3(2):42-8.
    View in: PubMed
    Score: 0.006
  35. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
    View in: PubMed
    Score: 0.006
  36. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. Circulation. 2021 11 02; 144(18):1521-1523.
    View in: PubMed
    Score: 0.006
  37. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. Chest. 2001 Aug; 120(2):453-9.
    View in: PubMed
    Score: 0.006
  38. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001 Apr 24; 103(16):2055-9.
    View in: PubMed
    Score: 0.006
  39. Cardiovascular Toxicities of Androgen Deprivation Therapy. Curr Treat Options Oncol. 2021 04 17; 22(6):47.
    View in: PubMed
    Score: 0.006
  40. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis Rheumatol. 2021 05; 73(5):866-874.
    View in: PubMed
    Score: 0.006
  41. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.006
  42. Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. J Am Heart Assoc. 2020 10 20; 9(19):e014669.
    View in: PubMed
    Score: 0.006
  43. Home Health Care Use and Post-Discharge Outcomes After Heart?Failure Hospitalizations. JACC Heart Fail. 2020 12; 8(12):1038-1049.
    View in: PubMed
    Score: 0.005
  44. Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. Circ Heart Fail. 2020 03; 13(3):e006513.
    View in: PubMed
    Score: 0.005
  45. Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. Am J Nephrol. 2020; 51(3):172-181.
    View in: PubMed
    Score: 0.005
  46. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29; 99(25):3224-6.
    View in: PubMed
    Score: 0.005
  47. Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. Am J Kidney Dis. 2019 11; 74(5):650-658.
    View in: PubMed
    Score: 0.005
  48. Understanding by General Providers of the Echocardiogram Report. Am J Cardiol. 2019 07 15; 124(2):296-302.
    View in: PubMed
    Score: 0.005
  49. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.005
  50. Implantable Ventricular Assist Device Use and Outcomes in People With End-Stage Renal Disease. J Am Heart Assoc. 2018 07 06; 7(14).
    View in: PubMed
    Score: 0.005
  51. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.005
  52. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
    View in: PubMed
    Score: 0.005
  53. Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. Am J Kidney Dis. 2018 10; 72(4):620-622.
    View in: PubMed
    Score: 0.005
  54. De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. Am J Kidney Dis. 2018 08; 72(2):223-233.
    View in: PubMed
    Score: 0.005
  55. Short-Term Global Cardiovascular Disease Risk?Prediction in Older Adults. J Am Coll Cardiol. 2018 06 05; 71(22):2527-2536.
    View in: PubMed
    Score: 0.005
  56. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.005
  57. Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. Am J Cardiol. 2017 06 15; 119(12):2030-2034.
    View in: PubMed
    Score: 0.004
  58. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail. 2016 08; 9(8).
    View in: PubMed
    Score: 0.004
  59. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.004
  60. Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. Clin Cardiol. 2016 Mar; 39(3):145-9.
    View in: PubMed
    Score: 0.004
  61. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016 Feb 16; 133(7):631-8.
    View in: PubMed
    Score: 0.004
  62. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015 Oct 20; 66(16):1803-1812.
    View in: PubMed
    Score: 0.004
  63. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circ Heart Fail. 2015 Nov; 8(6):1052-8.
    View in: PubMed
    Score: 0.004
  64. Response to Letter Regarding Article, ?Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction?. Circ Heart Fail. 2015 Jul; 8(4):840.
    View in: PubMed
    Score: 0.004
  65. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
    View in: PubMed
    Score: 0.004
  66. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail. 2015 May; 8(3):533-41.
    View in: PubMed
    Score: 0.004
  67. Coronary artery disease performance measures and statin use in patients with recent percutaneous coronary intervention or recent coronary artery bypass grafting (from the NCDR PINNACLE registry). Am J Cardiol. 2015 Apr 15; 115(8):1013-8.
    View in: PubMed
    Score: 0.004
  68. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.004
  69. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. Eur Heart J. 2015 Apr 14; 36(15):939-45.
    View in: PubMed
    Score: 0.004
  70. Case report: isolated cardiac amyloidosis: an enigma unravelled. Methodist Debakey Cardiovasc J. 2015 Jan-Mar; 11(1):53-8.
    View in: PubMed
    Score: 0.004
  71. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):21-6.
    View in: PubMed
    Score: 0.004
  72. Relation between playing position and coronary artery calcium scores in retired National Football League players. Am J Cardiol. 2014 Dec 15; 114(12):1836-40.
    View in: PubMed
    Score: 0.004
  73. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail. 2014 Aug; 2(4):412-21.
    View in: PubMed
    Score: 0.004
  74. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18; 310(23):2533-43.
    View in: PubMed
    Score: 0.003
  75. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail. 2014 Jan; 7(1):123-30.
    View in: PubMed
    Score: 0.003
  76. Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Oct; 31(5):291-7.
    View in: PubMed
    Score: 0.003
  77. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.003
  78. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar 27; 309(12):1268-77.
    View in: PubMed
    Score: 0.003
  79. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 Dec 13; 367(24):2296-304.
    View in: PubMed
    Score: 0.003
  80. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012 Nov; 164(5):763-770.e3.
    View in: PubMed
    Score: 0.003
  81. Echocardiographic changes during treatment of acute decompensated heart failure: insights from the ESCAPE trial. J Card Fail. 2012 Oct; 18(10):792-8.
    View in: PubMed
    Score: 0.003
  82. Worsening renal function is not associated with response to treatment in acute heart failure. Int J Cardiol. 2013 Sep 01; 167(5):1912-7.
    View in: PubMed
    Score: 0.003
  83. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail. 2012 Mar 01; 5(2):152-9.
    View in: PubMed
    Score: 0.003
  84. New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. J Card Fail. 2012 Mar; 18(3):183-93.
    View in: PubMed
    Score: 0.003
  85. Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol. 2013 Jun 20; 166(2):394-8.
    View in: PubMed
    Score: 0.003
  86. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012 Mar; 21(3):233-40.
    View in: PubMed
    Score: 0.003
  87. New predictive models of heart failure mortality using time-series measurements and ensemble models. Circ Heart Fail. 2011 Jul; 4(4):456-62.
    View in: PubMed
    Score: 0.003
  88. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 03; 364(9):797-805.
    View in: PubMed
    Score: 0.003
  89. Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. Am Heart J. 2011 Mar; 161(3):567-73.
    View in: PubMed
    Score: 0.003
  90. The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. Am J Epidemiol. 2010 Oct 01; 172(7):781-9.
    View in: PubMed
    Score: 0.003
  91. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vasc Health Risk Manag. 2010 Aug 09; 6:449-55.
    View in: PubMed
    Score: 0.003
  92. Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. Int J Cardiol. 2011 Aug 04; 150(3):264-9.
    View in: PubMed
    Score: 0.003
  93. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010 Feb 01; 105(3):373-7.
    View in: PubMed
    Score: 0.003
  94. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol. 2009 Jul 15; 104(2):270-5.
    View in: PubMed
    Score: 0.003
  95. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009 May; 15(4):293-9.
    View in: PubMed
    Score: 0.002
  96. The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. Am J Surg. 2008 Nov; 196(5):720-5.
    View in: PubMed
    Score: 0.002
  97. The metabolic syndrome and mortality in an ethnically diverse heart failure population. J Card Fail. 2008 Sep; 14(7):590-5.
    View in: PubMed
    Score: 0.002
  98. Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. Chest. 2003 Mar; 123(3):716-24.
    View in: PubMed
    Score: 0.002
  99. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
    View in: PubMed
    Score: 0.002
  100. Quantification of the myocardial response to low-dose dobutamine using tissue Doppler echocardiographic measures of velocity and velocity gradient. Am J Cardiol. 1998 Mar 01; 81(5):615-23.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.